Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.49 |
| ▸ | IDH2 | P48735 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | GPR4 | P46093 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26081091 | 0.89 | IDH1 (0.51) | IDH1IDH2TACR1RORCHRH3 | |
| SCHEMBL16049825 | 0.87 | PKLR (0.48) | TACR1GPR4OPRD1OPRK1CYP11B2 | |
| SCHEMBL16049607 | 0.85 | GPR4 (0.49) | TACR1GPR4OPRD1OPRK1CYP11B2 | |
| SCHEMBL29686152 | 0.85 | GPR4 (0.49) | TACR1GPR4OPRD1OPRK1CYP11B2 | |
| SCHEMBL1054762 | 0.84 | POLB (0.43) | GPR4OPRD1OPRK1CYP11B2KDM1A | |
| SCHEMBL30328833 | 0.82 | IDH1 (0.47) | IDH1IDH2TACR1RORCCYP11B2 | |
| SCHEMBL1760964 | 0.81 | IDH1 (0.51) | IDH1IDH2TACR1RORCHRH3 | |
| SCHEMBL30585014 | 0.80 | CYP46A1 (0.54) | OPRD1OPRK1 | |
| SCHEMBL1088021 | 0.80 | CYP46A1 (0.54) | OPRD1OPRK1 | |
| SCHEMBL7511633 | 0.79 | BACE1 (0.45) | GPR4OPRD1OPRK1CYP11B2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | IDH1 887/4885IDH2 631/4885TACR1 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.